Serum Vasostatin-1 Level is Increased in Women with Preeclampsia

 

 Buy Article Permissions and Reprints

Abstract

Objective To evaluate the serum vasostatin-1 levels in preeclamptic and non-preeclamptic pregnant women.

Materials and methods Thirty consecutive women with mild preeclampsia and sixty consecutive women with severe preeclampsia were compared with ninety gestational age-matched (±1 week) non-preeclamptic pregnant women with an appropriate-for-gestational-age (AGA) fetus.

Results Mean serum vasostatin-1 was significantly higher in women with preeclampsia than gestational age-matched controls. Mean serum vasostatin-1 was significantly higher in the mild preeclampsia group compared to its gestational age-matched control group, and in the severe preeclampsia group compared to its gestational age-matched control group. There was no significant difference in mean serum vasostatin-1 levels between the mild and severe preeclampsia groups, and in severe early- and severe late-onset preeclampsia groups. Serum vasostatin-1 had positive correlations with systolic and diastolic blood pressure.

Conclusion Serum vasostatin-1 was significantly higher in women with preeclampsia compared to those of the gestational age-matched controls. There was no significant difference in mean serum vasostatin-1 levels between the mild and severe preeclampsia groups and severe early- and severe late-onset preeclampsia groups.

Publication History

Received: 19 July 2021

Accepted after revision: 11 January 2022

Article published online:
18 February 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Rana S, Lemoine E, Granger JP. et al. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res 2019; 124: 1094-1112
  Google Scholar
• 2 Sircar MT, Karumanchi SA. Pathogenesis of preeclampsia. Curr Opin Nephrol Hypertens 2015; 24: 131-138
  CrossrefPubMedGoogle Scholar
• 3 Roberts JM, Taylor RN, Musci TJ. et al. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989; 161: 1200-1204
  CrossrefPubMedGoogle Scholar
• 4 Dekker GA, van Geijn HP. Endothelial dysfunction in preeclampsia. Part I: Primary prevention. Therapeutic perspectives. J Perinat Med 1996; 24: 99-117
  CrossrefPubMedGoogle Scholar
• 5 Helle KB. The chromogranin A-derived peptides vasostatin-I and catestatin as regulatory peptides for cardiovascular functions. Cardiovasc Res 2010; 85: 9-16
  CrossrefPubMedGoogle Scholar
• 6 Angeletti RH, Aardal S, Serck-Hanssen G. et al. Vasoinhibitory activity of synthetic peptides from the amino terminus of chromogranin A. Acta Physiol Scand 1994; 152: 11-19
  CrossrefPubMedGoogle Scholar
• 7 Blois A, Srebro B, Mandala M. et al. The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells. Regul Pept 2006; 135: 78-84
  CrossrefPubMedGoogle Scholar
• 8 Ferrero E, Scabini S, Magni E. et al. Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage. FASEB J 2004; 18: 554-556
  CrossrefPubMedGoogle Scholar
• 9 Huegel R, Velasco P, De la Luz Sierra M. et al. Novel anti-inflammatory properties of the angiogenesis inhibitor vasostatin. J Invest Dermatol 2007; 127: 65-74
  CrossrefPubMedGoogle Scholar
• 10 Crippa L, Bianco M, Colombo B. et al. A new chromogranin A-dependent angiogenic switch activated by thrombin. Blood 2013; 121: 392-402
  CrossrefPubMedGoogle Scholar
• 11 Poon LC, Shennan A, Hyett JA. et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet 2019; 145 Suppl 1: 1-33
  CrossrefPubMedGoogle Scholar
• 12 Lain KY, Roberts JM. Contemporary concepts of the pathogenesis and management of preeclampsia. JAMA 2002; 287: 3183-3186
  CrossrefPubMedGoogle Scholar
• 13 Murthi P, Brennecke SP. The placenta is the villain or victim in the pathogenesis of pre-eclampsia: FOR: The placenta is the villain in the pathogenesis of preeclampsia. BJOG 2021; 128: 147
  CrossrefPubMedGoogle Scholar
• 14 Brosens I, Puttemans P, Benagiano G. Placental bed research: I. The placental bed: from spiral arteries remodeling to the great obstetrical syndromes. Am J Obstet Gynecol 2019; 221: 437-456
  CrossrefPubMedGoogle Scholar
• 15 Staff AC. The two-stage placental model of preeclampsia: an update. J Reprod Immunol 2019; 134–135: 1-10
  CrossrefPubMedGoogle Scholar
• 16 Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180: 499-506
  CrossrefPubMedGoogle Scholar
• 17 Roberts JM, Taylor RN, Goldfien A. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am J Hypertens 1991; 4: 700-708
  CrossrefPubMedGoogle Scholar
• 18 Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-10934
  CrossrefPubMedGoogle Scholar
• 19 Bardin N, Murthi P, Alfaidy N. Normal and pathological placental angiogenesis. Biomed Res Int 2015; 2015: 354359
  CrossrefPubMedGoogle Scholar
• 20 Venkatesha S, Toporsian M, Lam C. et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642-649
  CrossrefPubMedGoogle Scholar
• 21 Maynard SE, Min JY, Merchan J. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658
  CrossrefPubMedGoogle Scholar
• 22 Levine RJ, Lam C, Qian C. et al. Soluble endoglin and other circulating anti-angiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992-1005
  CrossrefPubMedGoogle Scholar
• 23 Salahuddin S, Lee Y, Vadnais M. et al. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol 2007; 197: 28.e1-6
  CrossrefPubMedGoogle Scholar
• 24 Levine RJ, Maynard SE, Qian C. et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683
  CrossrefPubMedGoogle Scholar
• 25 Rana S, Powe CE, Salahuddin S. et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125: 911-919
  CrossrefPubMedGoogle Scholar
• 26 Belloni D, Scabini S, Foglieni C. et al. The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration. FASEB J 2007; 21: 3052-3062
  CrossrefPubMedGoogle Scholar
• 27 Veschini L, Crippa L, Dondossola E. et al. The vasostatin-1 fragment of chromogranin A preserves a quiescent phenotype in hypoxia-driven endothelial cells and regulates tumor neovascularization. FASEB J 2011; 25: 3906-3914
  CrossrefPubMedGoogle Scholar
• 28 Ayaz E, Nergiz Y, Tunik S. et al. The comparison of endogenous angiogenesis inhibitors in normotensive and preeclamptic placentas: an immunohistochemical study. Hypertens Pregnancy 2014; 33: 61-71
  CrossrefPubMedGoogle Scholar
• 29 Pasqua T, Corti A, Gentile S. et al. Full-length human chromogranin-A cardioactivity: myocardial, coronary, and stimulus-induced processing evidence in normotensive and hypertensive male rat hearts. Endocrinology 2013; 154: 3353-3365
  CrossrefPubMedGoogle Scholar
• 30 Leung SW, Vanhoutte PM. Endothelium-dependent hyperpolarization: age, gender and blood pressure, do they matter?. Acta Physiol (Oxf) 2017; 219: 108-123
  CrossrefPubMedGoogle Scholar
• 31 Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011; 17: 1410-1422
  CrossrefPubMedGoogle Scholar
• 32 Baghai TC, Varallo-Bedarida G, Born C. et al. Classical risk factors and inflammatory biomarkers: one of the missing biological links between cardiovascular disease and major depressive disorder. Int J Mol Sci 2018; 19: 1740
  CrossrefPubMedGoogle Scholar
• 33 Sun HJ, Wu ZY, Nie XW. et al. Role of endothelial dysfunction in cardiovascular diseases: the link between inflammation and hydrogen sulfide. Front Pharmacol 2019; 10: 1568
  CrossrefPubMedGoogle Scholar
• 34 Tota B, Angelone T, Cerra MC. The surging role of Chromogranin A in cardiovascular homeostasis. Front Chem 2014; 2: 64
  CrossrefPubMedGoogle Scholar
• 35 Angelone T, Mazza R, Cerra MC. Chromogranin-A: a multifaceted cardiovascular role in health and disease. Curr Med Chem 2012; 19: 4042-4050
  CrossrefPubMedGoogle Scholar
• 36 Aardal S, Helle KB. The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul Pept 1992; 41: 9-18
  CrossrefPubMedGoogle Scholar
• 37 Helle KB, Corti A, Metz-Boutigue MH. et al. The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci 2007; 64: 2863-2886
  CrossrefPubMedGoogle Scholar
• 38 Troger J, Theurl M, Kirchmair R. et al. Granin-derived peptides. Prog Neurobiol 2017; 154: 37-61
  CrossrefPubMedGoogle Scholar
• 39 Bianco M, Gasparri A, Generoso L. et al. Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models. Oncotarget 2016; 7: 41725-41736
  CrossrefPubMedGoogle Scholar
• 40 Rumio C, Dusio GF, Colombo B. et al. The N-terminal fragment of chromogranin A, vasostatin-1 protects mice from acute or chronic colitis upon oral administration. Dig Dis Sci 2012; 57: 1227-1237
  CrossrefPubMedGoogle Scholar
• 41 Rocca C, Scavello F, Colombo B. et al. Physiological levels of chromogranin A prevent doxorubicin-induced cardiotoxicity without impairing its anticancer activity. FASEB J 2019; 33: 7734-7747
  CrossrefPubMedGoogle Scholar
• 42 Karumanchi SA, Granger JP. Preeclampsia and pregnancy-related hypertensive disorders. Hypertension 2016; 67: 238-242
  CrossrefPubMedGoogle Scholar
• 43 Spradley FT. Sympathetic nervous system control of vascular function and blood pressure during pregnancy and preeclampsia. J Hypertens 2019; 37: 476-487
  CrossrefPubMedGoogle Scholar
• 44 Ceconi C, Ferrari R, Bachetti T. et al. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J 2002; 23: 967-974
  CrossrefPubMedGoogle Scholar

• Supplementary Material